Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera

PHASE4CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

March 12, 2015

Primary Completion Date

February 16, 2017

Study Completion Date

April 27, 2017

Conditions
Multiple Sclerosis
Interventions
DRUG

dimethyl fumarate

Starting dose of 120 mg twice daily orally After 7 days, maintenance dose of 240 mg twice daily orally

DRUG

montelukast

As described in the treatment arm

DRUG

Placebo

Matched placebo

Trial Locations (50)

10029

Research Site, New York

11772

Research Site, Patchogue

14226

Research Site, Amherst

15601

Research Site, Greensburg

17033

Research Site, Hershey

18519

Research Site, Dickson City

18711

Research Site, Wilkes-Barre

20057

Research Site, Washington D.C.

22310

Research Site, Alexandria

23601

Research Site, Newport News

27103

Research Site, Winston-Salem

27330

Research Site, Sanford

28792

Research Site, Hendersonville

30269

Research Site, Smyrna

32216

Research Site, Jacksonville

33351

Research Site, Sunrise

34102

Research Site, Naples

37215

Research Site, Nashville

40207

Research Site, Louisville

44685

Research Site, Uniontown

45417

Research Site, Dayton

45459

Research Site, Dayton

46256

Research Site, Indianapolis

48334

Research Site, Farmington Hills

53705

Research Site, Madison

60422

Research Site, Flossmoor

60612

Research Site, Chicago

63017

Research Site, Chesterfield

63104

Research Site, St Louis

64111

Research Site, Kansas City

72401

Research Site, Jonesboro

73109

Research Site, Oklahoma City

75214

Research Site, Dallas

78681

Research Site, Round Rock

80045

Research Site, Aurora

80907

Research Site, Colorado Springs

91767

Research Site, Pomona

91942

Research Site, La Mesa

92037

Research Site, La Jolla

93065

Research Site, Simi Valley

95608

Research Site, Carmichael

97062

Research Site, Tualatin

97225

Research Site, Portland

98122

Research Site, Seattle

06824

Research Site, Fairfield

32174-3102

Research Site, Ormond Beach

30165-1625

Research Site, Rome

04074

Research Site, Scarborough

07728

Research Site, Freehold

27607-6010

Research Site, Raleigh

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY

NCT02410278 - Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera | Biotech Hunter | Biotech Hunter